Details of the Drug
General Information of Drug (ID: DMFOM10)
Drug Name |
8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
8-Methoxy-2-aminotetralin; 3880-77-1; 8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine; CHEMBL26688; ACMC-20msdp; ACMC-20mscg; 2-amino-8-methoxytetralin; 8-methoxytetralin-2-amine; 8-methoxy-2-amino-tetralin; 2-Naphthalenamine,1,2,3,4-tetrahydro-8-methoxy-, (2R)-; 2-Naphthalenamine,1,2,3,4-tetrahydro-8-methoxy-, (2S)-; SCHEMBL266921; CTK4I0515; 2-NAPHTHALENAMINE, 1,2,3,4-TETRAHYDRO-8-METHOXY-; RVKOHSCTEHZRRT-UHFFFAOYSA-N; MFCD00906373; BDBM50016733; AKOS022393176; FCH1122360
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 177.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||